Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?

J Psychopharmacol. 2023 Nov;37(11):1157-1160. doi: 10.1177/02698811231179808. Epub 2023 Jun 10.

Authors

Premysl Vlcek^{1

2

3}, Petr Bob², Karel Vales^{1

3}

Affiliations

¹ National Institute of Mental Health, Klecany, Czech Republic.
² Department of Psychiatry, First Faculty of Medicine, Prague, Czech Republic.
³ Department of Psychiatry and Medical Psychology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.

PMID: 37300415
DOI: 10.1177/02698811231179808

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Comorbidity
Depression / drug therapy
Humans
Male
Monoamine Oxidase
Monoamine Oxidase Inhibitors* / pharmacology
Monoamine Oxidase Inhibitors* / therapeutic use
Prostatic Neoplasms* / drug therapy

Substances

Monoamine Oxidase Inhibitors
Monoamine Oxidase